Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8535883 | 0.93 | SLC6A4 (0.45) | SLC6A4SLC6A3SLC6A2PIM1PIM2 | |
| SCHEMBL22816524 | 0.82 | MMP1 (0.41) | SLC6A4SLC6A3SLC6A2PIM1PIM2 | |
| SCHEMBL626337 | 0.81 | HDAC6 (0.42) | PIM1PIM2HSD11B1EPHX2 | |
| SCHEMBL13107029 | 0.77 | ALDH1A1 (0.44) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL626533 | 0.77 | SLC6A3 (0.45) | SLC6A4SLC6A3SLC6A2PIM1PIM2 | |
| SCHEMBL7263445 | 0.76 | SLC6A4 (0.48) | SLC6A4SLC6A3SLC6A2PIM1PIM2 | |
| SCHEMBL28888791 | 0.76 | SLC6A4 (0.49) | SLC6A4SLC6A3SLC6A2PIM1PIM2 | |
| SCHEMBL4554666 | 0.75 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2PIM1PIM2 | |
| SCHEMBL12020399 | 0.74 | LIG1 (0.41) | SLC6A4SLC6A3SLC6A2HSD11B1 | |
| SCHEMBL4283467 | 0.74 | SLC6A4 (0.55) | SLC6A4SLC6A3SLC6A2PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-8772500-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| CN-103140476-A | Novel trpv3 modulators | ABBOTT LAB | 2013-06-05 | — | — | CN | disclosed |
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013062966-A2 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | SLC6A4 467/4885SLC6A3 553/4885SLC6A2 1157/4885 |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | SLC6A4 511/4885SLC6A3 717/4885SLC6A2 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.